Search Medical Condition
Please enter condition
Please choose location
Clear Trial Filters
 

Copenhagen O, Denmark Clinical Trials

A listing of Copenhagen O, Denmark clinical trials actively recruiting patients volunteers.

RESULTS

Found (26) clinical trials

Phase I Pharmacokinetics and Safety Study of Naloxegol in Paediatric OIC Patients

To characterize the pharmacokinetics (PK) of naloxegol after single oral dose and through population PK in paediatric patients with opioid induced constipation (OIC).

Phase

0.0 miles

Learn More »

Safety and Tolerability of ODM-203 in Subjects With Advanced Solid Tumours

The safety profile of ODM-203 will be explored together with the pharmacokinetics, pharmacodynamics and tumour response to treatment with ODM-203 to recommend the dosing regimen for further clinical studies. The pharmacokinetic properties of ODM 203 will be evaluated after single and multiple dose administrations at different dose levels

Phase

0.0 miles

Learn More »

Phase I/II Feasibility Study Combining Brentuximab Vedotin With Second Line Salvage Chemotherapy (DHAP) in Hodgkin Lymphoma Patients

To combine Brentuximab Vedotin with Dexamethasone, AraC and Cisplatin (DHAP) chemotherapy in patients with Hodgkin lymphoma (HL) refractory to first line chemotherapy or in first relapse is expected to induce a significantly higher (metabolic) complete remission (CR) rate prior to consolidation with BEAM, as judged by FDG (18F-2-fluoro-2-deoxy-D-glucose fluorodeoxyglucose)-PET negativity. ...

Phase

0.0 miles

Learn More »

SPATAX: Clinical and Genetic Analysis of Cerebellar Ataxias and Spastic Paraplegias

Cerebellar ataxias (CA) and spastic paraplegias (SP) are genetically and clinically very heterogeneous. More than 40 loci are already known but the number of phenotypes is even greater suggesting further genetic heterogeneity. These progressive disorders are often severe and fatal, due to the absence of specific therapy. The SPATAX network ...

Phase

1.41 miles

Learn More »

A Study of SAR428926 in Patients With Advanced Solid Tumors

The study duration for an individual patient will include a screening period for inclusion of up to 28 days, a treatment period, an end-of-treatment (EOT) visit around 30 days following the last administration of SAR428926, and at least one follow-up visit around 30 days after the EOT visit. The treatment ...

Phase

2.25 miles

Learn More »

A Study of RO7009789 in Combination With Atezolizumab in Participants With Locally Advanced and Metastatic Solid Tumors

This is an open-label, multicenter study designed to assess the safety, pharmacokinetics, pharmacodynamics and activity of RO7009789 administered in combination with atezolizumab (ATZ) in participants with metastatic or locally advanced solid tumors. The study will be conducted in three Parts (I, II, and III), with part I divided into Parts ...

Phase

2.25 miles

Learn More »

A Study of RO6958688 in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen Positive Solid Tumors

Study BP29541 is a first-in-human, open-label, multi-center, dose-escalation Phase I clinical study of single-agent RO6958688 in participants with locally advanced and/or metastatic carcinoembryonic antigen (CEA) positive solid tumors who have progressed on standard treatment, are intolerant to standard of care (SOC), and/or are non-amenable to SOC. The study will be ...

Phase

2.25 miles

Learn More »

A Study of Intravenous (IV) Cergutuzumab Amunaleukin and Atezolizumab in Combination in Participants With Locally Advanced and/or Metastatic Solid Tumors

This is an open-label, multi-center, Phase Ib clinical study of cergutuzumab amunaleukin, in combination with atezolizumab, to investigate the safety, pharmacokinetics, and therapeutic activity in participants with locally advanced and/or metastatic carcinoembryonic antigen (CEA)-positive solid tumors, whose disease has progressed on or who are intolerant to the standard of care ...

Phase

2.25 miles

Learn More »

A Phase I Multi-center Open Label Drug-drug Interaction Study to Assess the Effect of Ceritinib on the Pharmacokinetics of Warfarin and Midazolam in Patients With ALK-positive Advanced Tumors

The purpose of this study is to evaluate the potential inhibitory effects of ceritinib on the CYP3A4- and CYP2C9-mediated metabolism of the probe drugs midazolam and warfarin, respectively, when administered simultaneously as a cocktail. The results obtained from this drug interaction study will provide guidance that will enable an update ...

Phase

2.25 miles

Learn More »

A Study Evaluating Safety Pharmacokinetics and Therapeutic Activity of RO6874281 in Participants With Advanced and/or Metastatic Solid Tumors

This open-label, multicenter, dose-escalation study will evaluate the safety, pharmacokinetics and therapeutic activity of RO6874281 in participants with advanced and/or metastatic solid tumors. Participants will be treated until disease progression or unacceptable toxicity occurs, for up to a maximum of 24 months.

Phase

2.25 miles

Learn More »